News
By Twesha Dikshit (Reuters) -European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo ...
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...
Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback